![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
SA Wrighton, WR Brian, MA Sari, M Iwasaki, FP Guengerich, JL Raucy, DT Molowa and M Vandenbranden
Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285.
The human P450III family has been shown to be composed of at least four members, P450IIIA3 (HLp), P450IIIA4 (P450NF), P450IIIA5 (HLp3), and P450IIIA6 (HLp2). Due to the lack of probes that specifically recognize the individual members of this family, little is known about their relative expression. We prepared a form-specific antibody to P450IIIA5 by immunoabsorption of anti-P450IIIA5 IgG against Sepharose 4B upon which microsomes that did not contain P450IIIA5 or purified P450IIIA3 had been bound. Immunoblot analyses demonstrated that P450IIIA5 was expressed at detectable levels in only 19 of 66 (29%) human livers. The expression of P450IIIA5 was not influenced by the gender or medical history of the patients. When the expression of P450IIIA5 in different age groups was examined, it was observed that P450IIIA5 was detected in a statistically significantly higher percentage of children and adolescents (19 years old and under), as compared with the remaining population (8 of 17, 47%, versus 11 of 46, 24%, respectively). Furthermore, P450IIIA5 was detected in 1 of 10 human fetal livers. Of the large number of compounds identified as substrates of P450III family members, P450IIIA5 was found to actively metabolize nifedipine, testosterone, estradiol, dehydroepiandrosterone 3-sulfate, and cortisol, whereas it metabolized poorly or did not metabolize erythromycin, quinidine, 17 alpha-ethynylestradiol, and aflatoxins. The acetylenic steroid gestodene was found to be an effective mechanism- based inhibitor of both P450IIIA4 and P450IIIA5. Immunoblots of microsomes isolated from untreated and dexamethasone-, phenobarbital-, or 3-methylcholanthrene-treated HepG2 cells that were developed with an antibody that recognizes all the P450III family members demonstrated that no proteins in the P450III family were expressed by the HepG2 cells. In conclusion, our studies indicate that P450IIIA5 is polymorphically expressed at all stages of human development and is more limited in its metabolic capabilities than is P450IIIA4.
This article has been cited by other articles:
|
|
 |
|
  S. Sharma, J. Ou, S. Strom, D. Mattison, S. Caritis, and R. Venkataramanan Identification of Enzymes Involved in the Metabolism of 17{alpha}-Hydroxyprogesterone Caproate: An Effective Agent for Prevention of Preterm Birth Drug Metab. Dispos., September 1, 2008; 36(9): 1896 - 1902. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Roberts, K. D. Rollins, A. D. M. Kashuba, M. F. Paine, A. C. Nelsen, E. E. Williams, C. Moran, J. K. Lamba, E. G. Schuetz, and R. L. Hawke The Influence of CYP3A5 Genotype on Dexamethasone Induction of CYP3A Activity in African Americans Drug Metab. Dispos., August 1, 2008; 36(8): 1465 - 1469. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-Y. Ku, H.-J. Ahn, K.-A. Seo, H. Kim, M. Oh, S. K. Bae, J.-G. Shin, J.-H. Shon, and K.-H. Liu The Contributions of Cytochromes P450 3A4 and 3A5 to the Metabolism of the Phosphodiesterase Type 5 Inhibitors Sildenafil, Udenafil, and Vardenafil Drug Metab. Dispos., June 1, 2008; 36(6): 986 - 990. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y.-J. Yoon, K.-B. Kim, H. Kim, K.-A. Seo, H.-S. Kim, I.-J. Cha, E.-Y. Kim, K.-H. Liu, and J.-G. Shin Characterization of Benidipine and Its Enantiomers' Metabolism by Human Liver Cytochrome P450 Enzymes Drug Metab. Dispos., September 1, 2007; 35(9): 1518 - 1524. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. Joy, S. L. Hogan, B. D. Thompson, W. F. Finn, and V. Nickeleit Cytochrome P450 3A5 expression in the kidneys of patients with calcineurin inhibitor nephrotoxicity Nephrol. Dial. Transplant., July 1, 2007; 22(7): 1963 - 1968. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A.-M. Moilanen, J. Hakkola, M. H. Vaarala, S. Kauppila, P. Hirvikoski, J. T. Vuoristo, R. J. Edwards, and T. K. Paavonen Characterization of androgen-regulated expression of CYP3A5 in human prostate Carcinogenesis, May 1, 2007; 28(5): 916 - 921. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.-l. Lin and P. F. Hollenberg The Inactivation of Cytochrome P450 3A5 by 17{alpha}-Ethynylestradiol Is Cytochrome b5-Dependent: Metabolic Activation of the Ethynyl Moiety Leads to the Formation of Glutathione Conjugates, a Heme Adduct, and Covalent Binding to the Apoprotein J. Pharmacol. Exp. Ther., April 1, 2007; 321(1): 276 - 287. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. M. Kent, H.-l. Lin, K. R. Noon, D. L. Harris, and P. F. Hollenberg Metabolism of Bergamottin by Cytochromes P450 2B6 and 3A5 J. Pharmacol. Exp. Ther., September 1, 2006; 318(3): 992 - 1005. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-K. Lee, J.-K. Moon, C.-H. Chang, H. Choi, H.-W. Park, B.-S. Park, H.-S. Lee, E.-C. Hwang, Y.-D. Lee, K.-H. Liu, et al. STEREOSELECTIVE METABOLISM OF ENDOSULFAN BY HUMAN LIVER MICROSOMES AND HUMAN CYTOCHROME P450 ISOFORMS Drug Metab. Dispos., July 1, 2006; 34(7): 1090 - 1095. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Shimizu, K. Akimoto, T. Yoshimura, T. Niwa, K. Kobayashi, M. Tsunoo, and K. Chiba AUTOINDUCTION OF MKC-963 [(R)-1-(1-CYCLOHEXYLETHYLAMINO)-4-PHENYLPHTHALAZINE] METABOLISM IN HEALTHY VOLUNTEERS AND ITS RETROSPECTIVE EVALUATION USING PRIMARY HUMAN HEPATOCYTES AND CDNA-EXPRESSED ENZYMES Drug Metab. Dispos., June 1, 2006; 34(6): 950 - 954. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Fakhoury, C. Litalien, Y. Medard, H. Cave, N. Ezzahir, M. Peuchmaur, and E. Jacqz-Aigrain LOCALIZATION AND mRNA EXPRESSION OF CYP3A AND P-GLYCOPROTEIN IN HUMAN DUODENUM AS A FUNCTION OF AGE Drug Metab. Dispos., November 1, 2005; 33(11): 1603 - 1607. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. B. Koukouritaki, M. T. Poch, E. T. Cabacungan, D. G. McCarver, and R. N. Hines Discovery of Novel Flavin-Containing Monooxygenase 3 (FMO3) Single Nucleotide Polymorphisms and Functional Analysis of Upstream Haplotype Variants Mol. Pharmacol., August 1, 2005; 68(2): 383 - 392. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. L. Noreault, V. E. Kostrubsky, S. G. Wood, R. C. Nichols, S. C. Strom, H. W. Trask, S. A. Wrighton, R. M. Evans, J. M. Jacobs, P. R. Sinclair, et al. ARSENITE DECREASES CYP3A4 AND RXR{alpha} IN PRIMARY HUMAN HEPATOCYTES Drug Metab. Dispos., July 1, 2005; 33(7): 993 - 1003. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-N. Roy, J. Lajoie, L. S. Zijenah, A. Barama, C. Poirier, B. J. Ward, and M. Roger CYP3A5 GENETIC POLYMORPHISMS IN DIFFERENT ETHNIC POPULATIONS Drug Metab. Dispos., July 1, 2005; 33(7): 884 - 887. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y.-H. Wang, D. R. Jones, and S. D. Hall DIFFERENTIAL MECHANISM-BASED INHIBITION OF CYP3A4 AND CYP3A5 BY VERAPAMIL Drug Metab. Dispos., May 1, 2005; 33(5): 664 - 671. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-l. Lin, U. M. Kent, and P. F. Hollenberg The Grapefruit Juice Effect Is Not Limited to Cytochrome P450 (P450) 3A4: Evidence for Bergamottin-Dependent Inactivation, Heme Destruction, and Covalent Binding to Protein in P450s 2B6 and 3A5 J. Pharmacol. Exp. Ther., April 1, 2005; 313(1): 154 - 164. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.-J. Lee, D. A. Bell, S. J. Coulter, B. Ghanayem, and J. A. Goldstein Recombinant CYP3A4*17 Is Defective in Metabolizing the Hypertensive Drug Nifedipine, and the CYP3A4*17 Allele May Occur on the Same Chromosome as CYP3A5*3, Representing a New Putative Defective CYP3A Haplotype J. Pharmacol. Exp. Ther., April 1, 2005; 313(1): 302 - 309. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. F. Paine, S. S. Ludington, M.-L. Chen, P. W. Stewart, S.-M. Huang, and P. B. Watkins DO MEN AND WOMEN DIFFER IN PROXIMAL SMALL INTESTINAL CYP3A OR P-GLYCOPROTEIN EXPRESSION? Drug Metab. Dispos., March 1, 2005; 33(3): 426 - 433. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Huang, Y. S. Lin, D. J. McConn II, J. C. Calamia, R. A. Totah, N. Isoherranen, M. Glodowski, and K. E. Thummel EVIDENCE OF SIGNIFICANT CONTRIBUTION FROM CYP3A5 TO HEPATIC DRUG METABOLISM Drug Metab. Dispos., December 1, 2004; 32(12): 1434 - 1445. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. McConn II, Y. S. Lin, K. Allen, K. L. Kunze, and K. E. Thummel DIFFERENCES IN THE INHIBITION OF CYTOCHROMES P450 3A4 AND 3A5 BY METABOLITE-INHIBITOR COMPLEX-FORMING DRUGS Drug Metab. Dispos., October 1, 2004; 32(10): 1083 - 1091. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Kim, J. A. Johnson, and H. Derendorf Differences in Drug Pharmacokinetics Between East Asians and Caucasians and the Role of Genetic Polymorphisms J. Clin. Pharmacol., October 1, 2004; 44(10): 1083 - 1105. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Williams, J. Cook, and S. I. Hurst A SIGNIFICANT DRUG-METABOLIZING ROLE FOR CYP3A5? Drug Metab. Dispos., December 1, 2003; 31(12): 1526 - 1530. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. C. Stevens, R. N. Hines, C. Gu, S. B. Koukouritaki, J. R. Manro, P. J. Tandler, and M. J. Zaya Developmental Expression of the Major Human Hepatic CYP3A Enzymes J. Pharmacol. Exp. Ther., November 1, 2003; 307(2): 573 - 582. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. Plummer, D. V. Conti, P. L. Paris, A. P. Curran, G. Casey, and J. S. Witte CYP3A4 and CYP3A5 Genotypes, Haplotypes, and Risk of Prostate Cancer Cancer Epidemiol. Biomarkers Prev., September 1, 2003; 12(9): 928 - 932. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. N. Hines, Z. Luo, K. A. Hopp, E. T. Cabacungan, S. B. Koukouritaki, and D. G. McCarver Genetic Variability at the Human FMO1 Locus: Significance of a Basal Promoter Yin Yang 1 Element Polymorphism (FMO1*6) J. Pharmacol. Exp. Ther., September 1, 2003; 306(3): 1210 - 1218. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. C. Patki, L. L. von Moltke, and D. J. Greenblatt IN VITRO METABOLISM OF MIDAZOLAM, TRIAZOLAM, NIFEDIPINE, AND TESTOSTERONE BY HUMAN LIVER MICROSOMES AND RECOMBINANT CYTOCHROMES P450: ROLE OF CYP3A4 AND CYP3A5 Drug Metab. Dispos., July 1, 2003; 31(7): 938 - 944. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. R. Robertson, J. Field, B. Goodwin, S. Bierach, M. Tran, A. Lehnert, and C. Liddle Transgenic Mouse Models of Human CYP3A4 Gene Regulation Mol. Pharmacol., July 1, 2003; 64(1): 42 - 50. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Westlind-Johnsson, S. Malmebo, A. Johansson, C. Otter, T. B. Andersson, I. Johansson, R. J. Edwards, A. R. Boobis, and M. Ingelman-Sundberg COMPARATIVE ANALYSIS OF CYP3A EXPRESSION IN HUMAN LIVER SUGGESTS ONLY A MINOR ROLE FOR CYP3A5 IN DRUG METABOLISM Drug Metab. Dispos., June 1, 2003; 31(6): 755 - 761. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Anakk, C. Y. Ku, M. Vore, and H. W. Strobel Insights into Gender Bias: Rat Cytochrome P450 3A9 J. Pharmacol. Exp. Ther., May 1, 2003; 305(2): 703 - 709. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Treluyer, G. Bowers, N. Cazali, M. Sonnier, E. Rey, G. Pons, and T. Cresteil Oxidative Metabolism of Amprenavir in the Human Liver. Effect of the CYP3A Maturation Drug Metab. Dispos., March 1, 2003; 31(3): 275 - 281. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Hukkanen, T. Vaisanen, A. Lassila, R. Piipari, S. Anttila, O. Pelkonen, H. Raunio, and J. Hakkola Regulation of CYP3A5 by Glucocorticoids and Cigarette Smoke in Human Lung-Derived Cells J. Pharmacol. Exp. Ther., February 1, 2003; 304(2): 745 - 752. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P.-S. Shih and J.-D. Huang Pharmacokinetics of Midazolam and 1'-Hydroxymidazolam in Chinese with Different CYP3A5 Genotypes Drug Metab. Dispos., December 1, 2002; 30(12): 1491 - 1496. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Koch, R. Weil, R. Wolbold, J. Brockmoller, E. Hustert, O. Burk, A. Nuessler, P. Neuhaus, M. Eichelbaum, U. Zanger, et al. Interindividual Variability and Tissue-Specificity in the Expression of Cytochrome P450 3A mRNA Drug Metab. Dispos., October 1, 2002; 30(10): 1108 - 1114. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. K. Khan, Y. Q. He, M. A. Correia, and J. R. Halpert Differential Oxidation of Mifepristone by Cytochromes P450 3A4 and 3A5: Selective Inactivation of P450 3A4 Drug Metab. Dispos., September 1, 2002; 30(9): 985 - 990. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Williams, B. J. Ring, V. E. Cantrell, D. R. Jones, J. Eckstein, K. Ruterbories, M. A. Hamman, S. D. Hall, and S. A. Wrighton Comparative Metabolic Capabilities of CYP3A4, CYP3A5, and CYP3A7 Drug Metab. Dispos., August 1, 2002; 30(8): 883 - 891. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. S. Lin, A. L. S. Dowling, S. D. Quigley, F. M. Farin, J. Zhang, J. Lamba, E. G. Schuetz, and K. E. Thummel Co-Regulation of CYP3A4 and CYP3A5 and Contribution to Hepatic and Intestinal Midazolam Metabolism Mol. Pharmacol., July 1, 2002; 62(1): 162 - 172. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Asghar, J. C. Gorski, B. Haehner-Daniels, and S. D. Hall Induction of Multidrug Resistance-1 and Cytochrome P450 mRNAs in Human Mononuclear Cells by Rifampin Drug Metab. Dispos., January 1, 2002; 30(1): 20 - 26. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F.-C. Chou, S.-J. Tzeng, and J.-d. Huang Genetic Polymorphism of Cytochrome P450 3A5 in Chinese Drug Metab. Dispos., September 1, 2001; 29(9): 1205 - 1209. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Lee, J. W. Kosh, A. H. Conney, and B. T. Zhu Characterization of the NADPH-Dependent Metabolism of 17beta -Estradiol to Multiple Metabolites by Human Liver Microsomes and Selectively Expressed Human Cytochrome P450 3A4 and 3A5 J. Pharmacol. Exp. Ther., August 1, 2001; 298(2): 420 - 432. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. N. Hines, Z. Luo, T. Cresteil, X. Ding, R. A. Prough, J. L. Fitzpatrick, S. L. Ripp, K. C. Falkner, N.-L. Ge, A. Levine, et al. Molecular Regulation of Genes Encoding Xenobiotic-Metabolizing Enzymes: Mechanisms Involving Endogenous Factors Drug Metab. Dispos., April 13, 2001; 29(5): 623 - 633. [Abstract] [Full Text]
|
|
|
|
|
|
W. Zheng, F. Jin, L. A. Dunning, X.-O. Shu, Q. Dai, W.-Q. Wen, Y.-T. Gao, and J. L. Holtzman Epidemiological Study of Urinary 6{beta}-Hydroxycortisol to Cortisol Ratios and Breast Cancer Risk Cancer Epidemiol. Biomarkers Prev., March 1, 2001; 10(3): 237 - 242. [Abstract] [Full Text]
|
|
|
|
|
|
H. Echizen, M. Tanizaki, J. Tatsuno, K. Chiba, T. Berwick, M. Tani, F. J. Gonzalez, and T. Ishizaki Identification of CYP3A4 as the Enzyme Involved in the Mono-N-Dealkylation of Disopyramide Enantiomers in Humans Drug Metab. Dispos., August 1, 2000; 28(8): 937 - 944. [Abstract] [Full Text]
|
|
|
|
 |
|
 B. C. Krovat, J. H. Tracy, and C. J. Omiecinski Fingerprinting of Cytochrome P450 and Microsomal Epoxide Hydrolase Gene Expression in Human Blood Cells Toxicol. Sci., June 1, 2000; 55(2): 352 - 360. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Santos, S. Zanetta, T. Cresteil, A. Deroussent, F. Pein, E. Raymond, L. Vernillet, M.-L. Risse, V. Boige, A. Gouyette, et al. Metabolism of Irinotecan (CPT-11) by CYP3A4 and CYP3A5 in Humans Clin. Cancer Res., May 1, 2000; 6(5): 2012 - 2020. [Abstract] [Full Text]
|
|
|
|
|
|
V. E. Kostrubsky, V. Ramachandran, R. Venkataramanan, K. Dorko, J. E. Esplen, S. Zhang, J. F. Sinclair, S. A. Wrighton, and S. C. Strom The Use of Human Hepatocyte Cultures to Study the Induction of Cytochrome P-450 Drug Metab. Dispos., August 1, 1999; 27(8): 887 - 894. [Abstract] [Full Text]
|
|
|
|
|
|
T. Imai, M. Taketani, T. Suzu, K. Kusube, and M. Otagiri In Vitro Identification of the Human Cytochrome P-450 Enzymes Involved in the N-Demethylation of Azelastine Drug Metab. Dispos., August 1, 1999; 27(8): 942 - 946. [Abstract] [Full Text]
|
|
|
|
|
|
J. M. Fisher, S. A. Wrighton, P. B. Watkins, P. Schmiedlin-Ren, J. C. Calamia, D. D. Shen, K. L. Kunze, and K. E. Thummel First-Pass Midazolam Metabolism Catalyzed by 1alpha ,25-Dihydroxy Vitamin D3-Modified Caco-2 Cell Monolayers J. Pharmacol. Exp. Ther., May 1, 1999; 289(2): 1134 - 1142. [Abstract] [Full Text]
|
|
|
|
|
|
T. L. Nielsen, B. B. Rasmussen, J.-P. Flinois, P. Beaune, and K. Brøsen In Vitro Metabolism of Quinidine: The (3S)-3-Hydroxylation of Quinidine Is a Specific Marker Reaction for Cytochrome P-4503A4 Activity in Human Liver Microsomes J. Pharmacol. Exp. Ther., April 1, 1999; 289(1): 31 - 37. [Abstract] [Full Text]
|
|
|
|
|
|
M. A. Gibbs, K. E. Thummel, D. D. Shen, and K. L. Kunze Inhibition of Cytochrome P-450 3A (CYP3A) in Human Intestinal and Liver Microsomes: Comparison of Ki Values and Impact of CYP3A5 Expression Drug Metab. Dispos., February 1, 1999; 27(2): 180 - 187. [Abstract] [Full Text]
|
|
|
|
|
|
A. J. Draper, A. Madan, K. Smith, and A. Parkinson Development of a Non-High Pressure Liquid Chromatography Assay to Determine Testosterone Hydroxylase (CYP3A) Activity in Human Liver Microsomes Drug Metab. Dispos., April 1, 1998; 26(4): 299 - 304. [Abstract] [Full Text]
|
|
|
|
|
|
J. M. Grace, A. J. Aguilar, K. M. Trotman, and T. G. Brewer Metabolism of beta -Arteether to Dihydroqinghaosu by Human Liver Microsomes and Recombinant Cytochrome P450 Drug Metab. Dispos., April 1, 1998; 26(4): 313 - 317. [Abstract] [Full Text]
|
|
|
|
|
|
E. M. Laurenzana and S. M. Owens Metabolism of Phencyclidine by Human Liver Microsomes Drug Metab. Dispos., May 1, 1997; 25(5): 557 - 563. [Abstract] [Full Text]
|
|
|
|
|
|
L. Zhou, R. R. Erickson, J. P. Hardwick, S. S. Park, S. A. Wrighton, and J. L. Holtzman Catalysis of the Cysteine Conjugation and Protein Binding of Acetaminophen by Microsomes from a Human Lymphoblast Line Transfected with the cDNAs of Various Forms of Human Cytochrome P450 J. Pharmacol. Exp. Ther., May 1, 1997; 281(2): 785 - 790. [Abstract] [Full Text]
|
|
|
|
|
|
P. Schmiedlin-Ren, K. E. Thummel, J. M. Fisher, M. F. Paine, K. S. Lown, and P. B. Watkins Expression of Enzymatically Active CYP3A4 by Caco-2 Cells Grown on Extracellular Matrix-Coated Permeable Supports in the Presence of 1alpha ,25-Dihydroxyvitamin D3 Mol. Pharmacol., May 1, 1997; 51(5): 741 - 754. [Abstract] [Full Text]
|
|
|
|
|
|
M. E. Fitzsimmons and J. M. Collins Selective Biotransformation of the Human Immunodeficiency Virus Protease Inhibitor Saquinavir by Human Small-Intestinal Cytochrome P4503A4. Potential Contribution to High First-Pass Metabolism Drug Metab. Dispos., February 1, 1997; 25(2): 256 - 266. [Abstract] [Full Text]
|
|
 |
 |
 |
|
 |
 |
 |
